Chemical Engineering @ChemengFiles.Com

Cambridge Laboratories Limited has announced that its main product, Tetrabenazine, (known as NITOMAN (R) in Germany and other key territories in Europe and XENAZINE (R) in the UK, U.S. and other markets) has received the approval of the market in Spain through the Spanish Agency of Medicines and Health Products.

The company has also announced that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, in addition to renewing existing agreements enAustraliay New Zealand.

Cambridge Laboratories Limited has announced that its main product, Tetrabenazine, (known as NITOMAN (R) in Germany and other key territories in Europe and XENAZINE (R) in the UK, U.S. and other markets) has received the approval of the market in Spain through the Spanish Agency of Medicines and Health Products.

The company has also announced that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, in addition to renewing existing agreements enAustraliay New Zealand.

Researchers at the University of Zaragoza and Consejo Superior de Investigaciones Científicas (CSIC) have made new findings from the project ROSAS, dedicated to the study of free radicals - responsible, among other things, the aging celulary by extension-related diseases, such as hypertension, fibrosis, mitochondrial disease (included within the so-called rare diseases) or Alzheimer's. Research has been published in the journal Proceedings of the National Academy of
Science, Molecular and Cellular Biology and Molecular Cell.

Among other achievements, researchers have identified a biomarker that could serve as early warning of oxidative stress caused by free radicals and hence the risk of developing diseases such as hypertension or fibrosis. Specifically, scientists at the Centro de Investigaciones Biológicas CSIC in Madrid have identified a cellular enzyme, the GAPDH (glyceraldehyde 3-phosphate dehydrogenase), which in normal conditions, interacts with certain structural elements of the messenger RNA, resulting in a low production of endothelin -1, a peptide involved in regulating vascular tone and related diseases such as hypertension or fibrosis.

Researchers at the University of Zaragoza and Consejo Superior de Investigaciones Científicas (CSIC) have made new findings from the project ROSAS, dedicated to the study of free radicals - responsible, among other things, the aging celulary by extension-related diseases, such as hypertension, fibrosis, mitochondrial disease (included within the so-called rare diseases) or Alzheimer's. Research has been published in the journal Proceedings of the National Academy of
Science, Molecular and Cellular Biology and Molecular Cell.

Among other achievements, researchers have identified a biomarker that could serve as early warning of oxidative stress caused by free radicals and hence the risk of developing diseases such as hypertension or fibrosis. Specifically, scientists at the Centro de Investigaciones Biológicas CSIC in Madrid have identified a cellular enzyme, the GAPDH (glyceraldehyde 3-phosphate dehydrogenase), which in normal conditions, interacts with certain structural elements of the messenger RNA, resulting in a low production of endothelin -1, a peptide involved in regulating vascular tone and related diseases such as hypertension or fibrosis.